RxDoctor Payments Data

Megan Decenzo, PA

Physician Assistant · Loveland, CONPI 1124549241

Payments from drug & device makers

$2,117in general payments, 2019–2025

Across 105 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$440
  • AbbVie$417
  • Biohaven Pharmaceutical Holding Company Ltd.$122
  • Amgen$103
  • Novo Nordisk$92
  • Merck$78
  • plus $864 from 27 others

What the payments were for

  • Food & beverage$2,10599%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,117 in reported general payments places this provider in the 85th percentile of 2,849 physician assistant providers in Colorado.

See all physician assistant providers in Colorado

Medicare billing

Part B allowed, 2024
$72,732
Medicare patients
160
Services billed
1,084

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide28$62,706
XareltoRivaroxaban16$25,092
EliquisApixaban12$21,174
JardianceEmpagliflozin13$20,621
FarxigaDapagliflozin Propanediol15$15,857
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,497
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$3,038
Levothyroxine Sodium221$2,067
Rosuvastatin Calcium106$1,264
Duloxetine Hcl43$1,022
Albuterol Sulfate HfaAlbuterol Sulfate40$824
Omeprazole51$793
Losartan Potassium65$768
Atorvastatin Calcium127$712
Celecoxib12$617

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$92$62,70628 claims
Johnson & JohnsonXarelto$44$25,09216 claims
AstraZenecaFarxiga, Breztri Aerosphere$440$24,35428 claims
PfizerEliquis$16$21,17412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,849 physician assistant providers in Colorado.

Other physician assistant in Loveland

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →